AI Article Synopsis
- RSV is a major unmet vaccine need for infants, particularly in developed countries, and has seen over 40 years of unsuccessful attempts for human vaccination.
- The main challenges include severe disease peaks at 2-3 months, complex vaccine antigen behaviors, history of vaccine-related complications, and reliance on animal models that may not mimic human responses accurately.
- Possible solutions involve maternal immunization, innovative engineering of vaccine components, creating a safe immunization platform for infants, and improving animal models for better understanding vaccine effects.
Article Abstract
Respiratory syncytial virus (RSV) is the greatest remaining unmet infant vaccine need in developed countries and an important unmet infant vaccine need worldwide. More than 40 years of effort have yet to result in a licensed RSV vaccine for humans. Key challenges to RSV vaccine development include a peak of severe disease at 2-3 months of age, problematic biochemical behavior of key vaccine antigens, a history of vaccine-mediated disease enhancement, and reliance on animal models that may not accurately reflect human disease processes. Potential paths to overcome these challenges include maternal immunization, structure-based engineering of vaccine antigens, the design of a novel platform for safe infant immunization, and the development of improved animal models for vaccine-enhanced disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.coviro.2013.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!